SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris announced overwhelmingly positive topline data from the…

Pharvaris N.V. · 6-K filed Sep 8, 2026 at 06:51 ET

At the news

BULLISHIMPACT 8/10

6-K filed Sep 8, 2026 at 06:51 ET

Pharvaris announced overwhelmingly positive topline data from the CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for prophylaxis of HAE attacks. The study met its primary endpoint with an 83% attack rate reduction versus placebo (p<0.0001) and all secondary endpoints were met with statistical significance, with a well-tolerated safety profile. This data supports planned NDA submissions starting in the first half of 2027, positioning deucrictibant as a potential first-in-class oral therapy with injectable-like efficacy for both on-demand and prophylactic treatment, which is a transformative event for this late-stage biotech company.

  • Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in all three types of HAE.
  • 87% attack rate reduction versus placebo observed in HAE Type 1 or Type 2 patients.
  • All secondary efficacy endpoints met with statistical significance.
  • Deucrictibant XR was well tolerated with no treatment-related serious adverse events.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access